Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Notes Payables (2016 - 2017)

Gyre Therapeutics (GYRE) has disclosed Notes Payables for 3 consecutive years, with $5.1 million as the latest value for Q4 2017.

  • Quarterly Notes Payables fell 73.79% to $5.1 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Dec 2017, down 73.79% year-over-year, with the annual reading at $5.1 million for FY2017, 73.79% down from the prior year.
  • Notes Payables for Q4 2017 was $5.1 million at Gyre Therapeutics, down from $5.5 million in the prior quarter.
  • The five-year high for Notes Payables was $34.8 million in Q3 2015, with the low at $5.1 million in Q4 2017.
  • Average Notes Payables over 3 years is $20.8 million, with a median of $24.5 million recorded in 2016.
  • The sharpest move saw Notes Payables fell 14.69% in 2016, then crashed 81.5% in 2017.
  • Over 3 years, Notes Payables stood at $33.7 million in 2015, then plummeted by 42.5% to $19.4 million in 2016, then plummeted by 73.79% to $5.1 million in 2017.
  • According to Business Quant data, Notes Payables over the past three periods came in at $5.1 million, $5.5 million, and $5.8 million for Q4 2017, Q3 2017, and Q2 2017 respectively.